Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.58 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.58 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.58 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | FAP | Q12884 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13019620 | 0.84 | DPP4 (0.65) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL725579 | 0.79 | DPP4 (0.64) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL7891864 | 0.78 | DPP4 (0.67) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL17927708 | 0.77 | DPP4 (0.60) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL3807159 | 0.77 | DPP4 (0.38) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL29558815 | 0.76 | DPP4 (0.67) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL214373 | 0.76 | DPP4 (0.67) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL12257160 | 0.76 | DPP4 (0.79) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL10025043 | 0.76 | DPP4 (0.79) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL11995628 | 0.76 | DPP4 (0.79) | DPP4DPP8DPP9DPP7ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2270009-B1 | Process for the preparation of sitagliptin | DIPHARMA FRANCIS SRL (IT) | 2012-07-25 | — | — | EP | disclosed |
| US-8097724-B2 | Process for the preparation of Sitagliptin | DIPHARMA FRANCIS S.R.L. (IT) | 2012-01-17 | — | — | US | disclosed |
| EP-2270009-A1 | Process for the preparation of sitagliptin | Dipharma Francis S.r.l. (IT) | 2011-01-05 | — | — | EP | disclosed |
| US-20100331541-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN | DIPHARMA FRANCIS S.R.L. (IT) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331541-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN | DPP4, DPP7, DPP9 | DPP4 1/4885DPP8 4/4885DPP9 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.